



PRESS RELEASE Oct 29, 2020

SelectImmune Pharma signs an agreement for a Phase II study for the treatment against infectious diseases

SelectImmune Pharma can announce today that a second clinical study will encompass patients with recurrent acute cystitis. The company has signed an agreement with a leading global opinion maker in the field, and the study will be conducted in Germany. The study aims to examine if the treatment of acute cystitides with an interleukin-1 receptor blocker provides satisfactory healing compared with conventional treatment with antibiotics. Studies in animal models have shown that interleukin-1 receptor blockers inhibit the inflammatory process of acute cystitis, reduce symptoms and lead to lower levels of bacteria – an effect comparable to treatment with antibiotics.

Bacterial infections affect large sections of the population and are increasingly difficult to treat due to increased resistance to antibiotics. SelectImmune Pharma is developing immunotherapies that can complement or replace antibiotics. Studies in animal models have shown very promising results with reduced symptoms and increased killing of bacteria. As recently announced, an initial clinical study has revealed distinct positive therapeutic effects in a group of patients with chronic pain in the lower urinary tract.

Urinary tract infections (UTIs) are one of the world's most common infectious diseases and afflict about 150 million people every year. The need for alternative treatments of bacterial infections is currently very high, and potential markets for this are significant.

“SelectImmune Pharma has the expertise to develop new immunotherapies for this large patient group,” says Gabriela Godaly, CMO, SelectImmune Pharma.

“Our international contacts are of crucial importance in being able to conduct high-quality studies and reach clinical users,” says Catharina Svanborg, Chairman of the Board, SelectImmune Pharma.

For more information, please contact:

Catharina Svanborg
Chairman of the Board, SelectImmune Pharma AB
Tel: +46 709 42 65 49
E-mail: catharina.svanborg@med.lu.se

Ann Gidner
CEO, SelectImmune Pharma AB
Tel: +46 768 17 14 14
E-mail: ann.gidner@selectimmune.com

SelectImmune Pharma is a pharmaceutical company whose shares are traded on the Spotlight Stock Market. The company’s goal is to develop new immunotherapies, which act as immune enhancers and offer alternatives to antibiotics.